Colorectal Neoplasms, Hereditary Nonpolyposis Colorectal Cancer
Conditions
Keywords
Hereditary colorectal cancer, Microsatellite instability, Physician roles, Health care implementation, Intervention
Brief summary
The purpose of this study is to compare two different strategies to implement a new method to identify patients with HNPCC, which appeared cost-effective and feasible. The effectiveness, costs and feasibility of both of the implementation strategies will be assessed.
Detailed description
The Radboud University Nijmegen Medical Centre developed a new method to identify patients with HNPCC. This method appeared cost-effective and feasible. Using this new method 70% of the HNPCC patients will be identified as compared to less than 30% when the current method is used. However, this new method does not implement itself; large gaps exists between best evidence and daily practice. This study will compare an intensive strategy, consisting of distribution of educational materials, education, feedback and reminders, with a minimal strategy, only consisting of distribution of a critical care pathway. The aim is to find the most cost-effective strategy to implement the new method to identify patients with HNPCC in the Netherlands.
Interventions
BEHAVIORALEducation for professionals
BEHAVIORALDistribution of educational materials
BEHAVIORALFeedback for professionals
BEHAVIORALReminders for professionals
Sponsors
ZonMw: The Netherlands Organisation for Health Research and Development
Radboud University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Colorectal cancer before the age of 50 years * Second colorectal cancer at any age * Colorectal cancer and other HNPCC associated extracolonic cancer irrespective of age at diagnosis * Adenoma with high grade dysplasia diagnosed before the age of 40 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of inclusion of eligible CRC-patients for MSI testing by pathologists. | — |
| Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons. | — |
Secondary
| Measure | Time frame |
|---|---|
| Experiences with and acceptance of changed physician practice roles by patients and clinicians. | — |
| Cost efficacy of the implementation procedures. | — |
Countries
Netherlands
Contacts
Primary ContactLucy I Overbeek, MSc
Backup ContactNicoline Hoogerbrugge, MD PhD
Outcome results
None listed